List view / Grid view
28 October 2015 | By Victoria White
Imylgic is a genetically modified herpes simplex virus type 1 designed to replicate within tumours and produce an immunostimulatory protein called GM-CSF...
27 October 2015 | By Victoria White
Omecamtiv mecarbil demonstrated statistically significant improvements in several measures of cardiac function, including systolic ejection time, stroke volume and N-terminal-pro-brain natriuretic peptide...
23 October 2015 | By Victoria White
If approved by the European Commission, Imlygic would be the first in a class of novel agents known as oncolytic immunotherapies...
12 October 2015 | By Victoria White
Results from a Phase 4 study show that denosumab achieved greater gains in bone mineral density than zoledronic acid in postmenopausal women with osteoporosis...
24 September 2015 | By Victoria White
ABP 215 is being developed as a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb)...
17 September 2015 | By Victoria White
Under the terms of the acquisition agreement, Amgen will pay $300 million in cash at closing and up to $1.25 billion in additional payments...
3 September 2015 | By Victoria White
If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously for the treatment of SHPT in patients with chronic kidney disease...
28 August 2015 | By Victoria White
Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options...
6 August 2015 | By Victoria White
Dr. Reddy’s has entered into a strategic collaboration with Amgen to distribute three Amgen medicines in India in the areas of oncology and cardiology...
23 July 2015 | By Victoria White
Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma...
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
20 July 2015 | By
Amgen has announced the top-line results of a Phase 2 trial evaluating blinatumomab in adults with relapsed or refractory Ph+ B-cell precursor ALL...
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
27 May 2015 | By Victoria White
Primary results from a Phase 3 study demonstrates a significantly higher DRR in patients with metastatic melanoma receiving the talimogene laherparepvec...
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
